Drive by prescription drugs, national health spending up in 2019

National health spending reached $3.76 trillion in March 2019, a 4.6% jump from the same month in 2018, according to recent data from Altarum, underscoring signs of acceleration during the first quarter of 2019.

Over the same 12-month period, national GDP grew at a rate of 4.6%, with health spending making up 17.9% of GDP in March 2019.

Hospital spending and physician and clinical services spending made up more than half of total health spending during March 2019, representing 32% and 20% of the total, respectively. Nursing home care and home healthcare spending were 8% of total health spending. Overall, 85% of total health spending was on personal healthcare goods and services.

At 10% of total health spending, prescription drugs saw the biggest increase in spending during the 12-month period. This result was “surprising,” with a year-over-year growth rate of 8.7% in March, compared to 4.9% in December 2018. The hike in spending is the “highest monthly value” in the time series since October 2015.

The growth rate, which does not include rebates from manufacturers, comes at a time when the Trump administration has put forth several proposals and new regulations that could lower drug prices, one of the key drivers of higher prescription drug spending.

The slowest growing category was dental services expenditures, which rose 1.4% in March 2019.

The health spending growth is above the annual rate of 2.6% seen since the start of the recession. Beginning in December 2007 through March 2019, health spending has increased 33.9%, Altarum found. GDP, by comparison when excluding healthcare, fell more than 6% in mid-2009 and is only 16.6% above its December 2007 level. With health spending included, GDP was 19.3% above its December 2007 level.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.